Elaine Shum

TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation

Jessica Ho, Bobo Wing-Yee Mok, Laura Campisi et al. · Cell · 2021 · 120 citations · Full text

Top1 Inhibition Therapy, Immunology, Antiviral Response +1

Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy

Matthew D. Hellmann, Pasi A. Jänne, Mateusz Opyrchal et al. · Clinical Cancer Research · 2020 · 115 citations · Full text

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

Jacob Sands, Myung‐Ju Ahn, Aaron Lisberg et al. · Journal of Clinical Oncology · 2025 · 66 citations · Full text

1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

Luis Paz‐Ares, M-J. Ahn, Aaron Lisberg et al. · Annals of Oncology · 2023 · 48 citations

Actionable Genomic Alterations, Medicine, Tumor Immunity +6

Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT)

Nitin Ohri, Shruti Jolly, Benjamin T. Cooper et al. · Journal of Clinical Oncology · 2023 · 48 citations